News
Talecris will adopt name of Grifols, Inc. as two companies form teams to consolidate operations
RESEARCH TRIANGLE PARK, NC — Grifols, a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain, has begun to merge its operations with Talecris Biotherapeutics, the company said in a press release today.
Formal integration teams comprising representatives from both companies are now collaborating to develop systems and processes that will facilitate a smooth transition, the release said.
On June 1, Grifols acquired Talecris, the manufacturer of plasma products including Prolastin-C for Alpha-1 augmentation therapy. Talecris will adopt the Grifols, Inc. name as the North American corporate subsidiary of Grifols.
“The union of our two companies provides an infusion of energy and talent, and strengthens our commitment to our shared mission of providing life-saving therapies to patients with rare, chronic diseases,” said Victor Grifols, President and CEO of Grifols. “The strength of our combined company is not simply its size; rather, it is the potential to achieve more for patients in the future than either company would be able to accomplish on its own.”
Combining the respective capabilities of the two companies will allow Grifols to extract more products from each liter of plasma and thus increase the quantity of products and choices available to patients. The company’s expanded global footprint will also improve patient access to critical-care protein therapies that are not widely available in many countries, the release said.
